Want to see HK:6896 full AI Analyst Report?
6896 Stock Chart & Stats
HK$3.07
-HK$0.01(-0.32%)
At close: 4:00 PM EST
HK$3.07
-HK$0.01(-0.32%)
Day’s Range― - ―
52-Week RangeHK$1.89 - HK$3.80
Previous CloseN/A
Volume368.50K
Average Volume (3M)839.42K
Market Cap
HK$1.43B
Enterprise ValueHK$1.80K
Total Cash (Recent Filing)HK$1.08B
Total Debt (Recent Filing)HK$584.52M
Price to Earnings (P/E)5.9
Beta0.17
Next Earnings
Mar 31, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield17.3%
Share Statistics
EPS (TTM)0.33
Shares Outstanding739,302,000
10 Day Avg. Volume485,600
30 Day Avg. Volume839,424
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)1.47
Price to Sales (P/S)2.15
P/FCF Ratio25.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sustained High MarginsPersistently high gross and net margins indicate that Golden Throat has maintained strong economics across the reported period. This supports the company’s ability to absorb operating costs, fund marketing and distribution, and retain meaningful earnings from its branded consumer-health products.
Manageable Leverage And Solid ReturnsModerate leverage and historically healthy returns on equity provide a relatively sound financial foundation. Although returns dipped in 2025, the balance sheet description still indicates debt remains manageable, leaving the company with more flexibility than a highly leveraged operator.
Established Branded Retail ModelA recognized consumer-health brand supported by broad retail distribution gives Golden Throat an established route to consumers. This operating model can support recurring product sales across multiple everyday channels and provides a foundation for maintaining market presence over coming quarters.
Bears Say
Recent Revenue ContractionThe recent revenue decline and history of uneven top-line performance indicate that demand and growth are not consistently expanding. Continued softness would limit operating leverage, reduce reinvestment capacity, and make it harder for the company to convert its strong margins into sustained earnings growth.
Sharp Cash-flow DeteriorationThe steep decline in operating and free cash flow is a material weakness because accounting profitability is translating less effectively into cash. If the deterioration persists, Golden Throat may have less capacity to fund investment, dividends, or working-capital requirements internally.
Rising LeverageHigher debt relative to equity reduces financial flexibility at a time when revenue and cash generation have weakened. Even though leverage is described as manageable, the increase can raise financing pressure and constrain future capital allocation if earnings remain softer.
Golden Throat Holdings Group Co Ltd News
6896 FAQ
What was Golden Throat Holdings Group Co Ltd’s price range in the past 12 months?
Golden Throat Holdings Group Co Ltd lowest stock price was HK$1.89 and its highest was HK$3.80 in the past 12 months.
What is Golden Throat Holdings Group Co Ltd’s market cap?
Golden Throat Holdings Group Co Ltd’s market cap is HK$1.43B.
When is Golden Throat Holdings Group Co Ltd’s upcoming earnings report date?
Golden Throat Holdings Group Co Ltd’s upcoming earnings report date is Mar 31, 2027 which is in 190 days.
How were Golden Throat Holdings Group Co Ltd’s earnings last quarter?
Golden Throat Holdings Group Co Ltd released its earnings results on Aug 31, 2026. The company reported HK$0.073 earnings per share for the quarter.
Is Golden Throat Holdings Group Co Ltd overvalued?
According to Wall Street analysts Golden Throat Holdings Group Co Ltd’s price is currently Overvalued.
Does Golden Throat Holdings Group Co Ltd pay dividends?
Golden Throat Holdings Group Co Ltd pays a Annually dividend of HK$0.34 which represents an annual dividend yield of 17.3%. See more information on Golden Throat Holdings Group Co Ltd dividends here
What is Golden Throat Holdings Group Co Ltd’s EPS estimate?
Golden Throat Holdings Group Co Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Golden Throat Holdings Group Co Ltd have?
Golden Throat Holdings Group Co Ltd has 739,302,000 shares outstanding.
What happened to Golden Throat Holdings Group Co Ltd’s price movement after its last earnings report?
Golden Throat Holdings Group Co Ltd reported an EPS of HK$0.073 in its last earnings report. Following the earnings report the stock price went up 1.944%.
Which hedge fund is a major shareholder of Golden Throat Holdings Group Co Ltd?
Currently, no hedge funds are holding shares in HK:6896
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Golden Throat Holdings Group Co Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.01%
12-Months-Change
Fundamentals
Return on Equity
17.30%
Trailing 12-Months
Asset Growth
6.11%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Golden Throat Holdings Group Co Ltd
Golden Throat Holdings Group Company Limited operates as an investment holding entity primarily engaged in the production and distribution of pharmaceutical goods, health-focused foods, and various other products within the People's Republic of China. Among its offerings are the widely recognized Golden Throat lozenges, an over-the-counter remedy designed to alleviate discomfort from sore and dry throats, as well as hoarseness often stemming from acute pharyngitis. The company further expands its Golden Throat lozenge line with products like Dule lozenges and their sugar-free counterparts, available in diverse flavors including orange, fructus momordicae, chrysanthemum, American ginseng, and hawthorn. Additionally, Golden Throat manufactures the Yinxingye tablet, formulated to enhance blood circulation, disperse blood stasis, and clear energy pathways. Its product portfolio also encompasses herbal vegetable beverages, crafted to provide vocal comfort and soothe irritated throats. Beyond its domestic market, the company extends its reach globally, exporting its range of products to countries and regions such as the United States, Canada, Russia, the European Union, Australia, Southeast Asia, the Middle East, Mexico, and across Africa. Established in 1956, Golden Throat Holdings Group Company Limited maintains its corporate headquarters in Liuzhou, within the People's Republic of China.
Technical Analysis
China Traditional Chinese Medicine Holdings Co
―
Wai Yuen Tong Medicine Holdings Limited
―
PuraPharm Corp. Ltd.
―
Pak Fah Yeow International Limited
―
Jacobson Pharma Corporation Limited
―